Diphtheria, Tetanus and Pertussis (acellurar component) Booster (dtap) Vaccine 2025 - 2027 (2027 - 2028 and 2028 - 2029)

The Ministry of Social Affairs and Health (hereinafter ”STM”) and Finnish Institute for Health and Welfare (hereinafter "THL" or “Customer” ) request your tender for Diphtheria, Tetanus and Pertussis (acellurar component) Booster (dtap) Vaccine belonging to the National Vaccination Programme in Finland. The contract period is two years 2025 - 2027. The procurement contains two one-year contract period renewals (1 + 1) to extend the contract for the periods 2027 - 2028 and 2028 - 2029. Estimated quantity for the contract period including contract period renewals is 460,000 doses. Customer reserves the right to increase or decrease the ordered numbers of doses by up to 20%. The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition. The most economically advantageous Tender shall be a Tender with lowest price. Please note that all times given in the Call for Tender refer to local time in Finland. Call for Tenders, annexes: Annex 1 Contract Annex 2 JYSE 2014 SUPPLIES (updated version of April 2022) Annex 3 Delivery schedule Annex 4 Subcontractors Annex 5 Description of the Handi Service

The purpose of STM and the Customer is to procure Diphtheria, Tetanus and Pertussis (acellurar component) Booster (dtap) Vaccine required for the National Vaccination Programme in Finland. The tendered vaccine must be suitable for school-age children, adolescents and adults. The Customer should prefer syringes without fixed needles. This procurement is not divided into lots. According to Communicable Diseases Act (1227/2016) the Finnish Institute for Health and Welfare has an obligation to supervise the implementation of the national immunization programme and other general vaccinations and monitor the implementation and impact of the vaccinations. Implementing and supervising the implementation of the national immunization programme with one suitable vaccine is more practical than dividing the procurement for lots. There are several target groups eligible for the vaccine in the vaccination programme (for more information on vaccination programme see https://thl.fi/aiheet/infektiotaudit-ja-rokotukset/rokotteet-a-o/jaykkakouristus-kurkkumata-hinkuyska-polio-ja-hib-yhdistelmarokotteet/nuorten-ja-aikuisten-kurkkumata-jaykkakouristus-ja-hinkuyskarokote-dtap). From the point of view of the scope of the procurement, it would seem artificial and rather vague to divide the procurement into lots by different target groups, since in fact, it is partly impossible for the contracting entity to estimate the size of the different target groups with sufficient accuracy. Annual vaccine consumption for different target groups may vary (based on e.g the annual epidemiological situation and size of age cohort for target groups). Pursuant to Section 2 of the Act on Public Procurement and Concession Contracts (Procurement Act), the contracting entity shall endeavour to arrange their procurement operations so that procurements can be implemented with optimal economy, quality and orderliness, taking advantage of existing competitive conditions and allowing for environmental and social aspects. If the procurement were divided into lots, the price of the procurement would probably become more expensive, as prices have been higher in previous competitive tendering processes when contracting entity has procured smaller amounts for small risk-groups. This would not make economic sense. In practice, it would also be confusing for the vaccinating staff if different products (vaccine) were used for different target groups. The legal obligation to arrange (and supervise) the implementation of the national immunization programme shall meet its target with one dtap-vaccine. Several different vaccines and contracts would also bring an administrative unwanted burden to contracting entity. From logistical point of view as vaccines need cold chain distribution, it is more environmentally friendly to try to minimize cold chain deliveries for one possible supplier instead of many possible suppliers. More information about National Vaccination Programme and vaccinations can be found on the website of the Finnish Institute for Health and Welfare: https://thl.fi/aiheet/infektiotaudit-ja-rokotukset/rokotteet-a-o/jaykkakouristus-kurkkumata-hinkuyska-polio-ja-hib-yhdistelmarokotteet/nuorten-ja-aikuisten-kurkkumata-jaykkakouristus-ja-hinkuyskarokote-dtap The Customer will implement the procurement on behalf of STM. The roles of STM and Customer are described in more detail in section "Presentation of the contracting authority". The subject of procurement and the mandatory requirements relating to it are described in detail in this Call for Tender and its annexes. The contract will be awarded to one Supplier based on a comparison of tenders. If the Supplier during the contract period releases a modified vaccine, the Parties should agree to substitute the Article with the modified vaccine. In case of substitution, all terms and prices in the Contract shall apply without modification. CONTRACT PERIOD The Contract shall enter into a force once the competent signatories of both the Contracting Parties have duly signed the Contract. The Contract shall expire when all contractual duties and obligations have been performed by both Parties. However, the contract period shall be counted from the first day of the month on which the Supplier has handed over the first delivery of the Articles to the Customer´s pharmaceutical wholesaler. The Contract period is two (2) years from the date defined previously above and the estimated quantity to be purchased for this period is 240.000 +/- 20 % doses. After the contract period, the Customer reserves the right for the contract period renewals described in section "Description of renewals". Tenders will be compared in the manner described in section "Grounds for decision" of the Call for Tenders.